Trial reportSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025
[Efficacy of β-Blockers in Older Adults With Hypertension Combined With Vascular Dementia].
Trial report in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical efficacy of β-blockers in older patients with hypertension combined with vascular dementia. Methods: A total of 152 older patients with hypertension combined with vascular dementia who were admitted to Shanxi Provincial Fenyang Hospital between January 2022 and October 2024 were enrolled. The participants were randomly assigned to either the study group or the control group (76 patients each) using the randomized numerical table method. Both groups received conventional treatment, and the study group received metoprolol for 5 weeks in addition to the conventional treatment. Primary outcome indicators, including changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) before and after treatment, were examined. Additionally, comparison was made to examine the intergroup difference in serological markers, including high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8, matrix metalloproteinase 9 (MMP-9), homocysteine (Hcy), and superoxide dismutase (SOD) levels, and the scores for intelligence, cognitive, and behavioral assessments. Adverse reactions were recorded. Results: After treatment, the study group showed reduced SBP from (146.90 ± 7.35) mmHg (1 mmHg = 0.133 kPa) to (120.00 ± 6.03) mmHg and reduced DBP from (90.24 ± 5.97) mmHg to (77.23 ± 6.81) mmHg. The reduction in blood pressure in the study group became more significantly when compared with that of the control group, with intergroup difference in SBP reduction being －8.54 mmHg ( Conclusion: The β-blocker metoprolol effectively controlled blood pressure, significantly reduced levels of pro-inflammatory factors and specific vascular injury markers, and improved cognitive function and behavioral symptoms in older patients with hypertension combined with vascular dementia, suggesting its therapeutic efficacy for this condition. However, attention should be paid to its associated adverse reactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.